Eli Lilly and Company $LLY Position Trimmed by OVERSEA CHINESE BANKING Corp Ltd

Key Points

• OVERSEA CHINESE BANKING Corp trimmed its stake in Eli Lilly by 22.4% in Q4, selling 4,611 shares and ending the quarter with 15,964 shares worth about $17.16 million.
• Newsflow is mixed: analyst upgrades, M&A and expanded distribution support the shares, but a softer-than-expected rollout of obesity pill Foundayo and mixed GLP‑1 prescription data raise near-term demand concerns ahead of the Q1 earnings report (due April 30).
• Eli Lilly remains large and highly owned by institutions (about 82.53%); the stock has a market cap of roughly $836B, a P/E of ~38.6, recent EPS beats and FY‑2026 guidance of 33.5–35.0 EPS, and an average analyst price target around $1,225 (Moderate Buy).

OVERSEA CHINESE BANKING Corp Ltd lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 22.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,964 shares of the company's stock after selling 4,611 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd's holdings in Eli Lilly and Company were worth $17,164,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Edge Financial Advisors LLC grew its stake in Eli Lilly and Company by 42.4% during the 4th quarter. Edge Financial Advisors LLC now owns 1,363 shares of the company's stock valued at $1,465,000 after acquiring an additional 406 shares in the last quarter. Hudson Value Partners LLC boosted its position in Eli Lilly and Company by 0.4% during the fourth quarter. Hudson Value Partners LLC now owns 2,782 shares of the company's stock valued at $2,998,000 after purchasing an additional 12 shares during the last quarter. Salomon & Ludwin LLC boosted its position in Eli Lilly and Company by 36.9% during the fourth quarter. Salomon & Ludwin LLC now owns 1,791 shares of the company's stock valued at $1,865,000 after purchasing an additional 483 shares during the last quarter. Penobscot Investment Management Company Inc. boosted its position in Eli Lilly and Company by 0.6% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 12,022 shares of the company's stock valued at $12,920,000 after purchasing an additional 77 shares during the last quarter. Finally, Morey & Quinn Wealth Partners LLC boosted its position in Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock valued at $710,000 after purchasing an additional 10 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly's obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Eli Lilly and Company Price Performance

NYSE LLY opened at $884.88 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock's 50-day moving average is $958.83 and its two-hundred day moving average is $983.91. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The firm has a market cap of $836.05 billion, a P/E ratio of 38.56, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company earned $5.32 earnings per share. The business's revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 33.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Scotiabank reissued an "outperform" rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Barclays assumed coverage on Eli Lilly and Company in a research report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 price objective for the company. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $1,285.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 6th. UBS Group reissued a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Finally, Morgan Stanley lifted their price objective on Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the company an "overweight" rating in a research report on Friday, April 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $1,225.33.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.